Home/Pipeline/CHIKV VLP Vaccine

CHIKV VLP Vaccine

Prevention of chikungunya virus infection

Phase 3Active

Key Facts

Indication
Prevention of chikungunya virus infection
Phase
Phase 3
Status
Active
Company

About Emergent BioSolutions

Emergent BioSolutions is a publicly traded biopharmaceutical company specializing in medical countermeasures against public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious diseases. The company operates through a fully integrated model encompassing development, manufacturing, and commercialization. Its portfolio includes FDA-approved products for anthrax, smallpox, botulism, and opioid overdose, positioning it as a critical partner to governments worldwide. Emergent's strategic focus is on preparedness and rapid response capabilities for health security emergencies.

View full company profile

Other Prevention of chikungunya virus infection Drugs

DrugCompanyPhase
VLA1553Bavarian NordicPhase 3